1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6D4A9E127EE15096B65258416003FF043
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-patient-advocacy-2020-abiding-ethical-boundaries-regulatory-impact-5563?opendocument
18
19opendocument
2035.173.234.140
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Patient Advocacy

Patient Advocacy 2020: Ethical Boundaries & Regulatory Impact on Patient Advocacy

ID: 5563


Features:

23 Info Graphics

4 Data Graphics

30+ Metrics

5 Narratives


Pages/Slides: 35


Published: 2019


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Patient Advocacy 2020: Ethical Boundaries & Regulatory Impact on Patient Advocacy”

STUDY OVERVIEW

Patient advocacy groups are an important partner for pharma in educating the marketplace about new medicines and treatments. Yet, the shifting regulatory landscape coupled with increased involvement of patient groups in key treatment and policy decisions is changing the advocacy relationship dynamics.

Best Practices, LLC undertook this benchmarking research to identify effective ways for biopharmaceutical organizations to collaborate with patient advocacy groups. In particular, this research establishes benchmarks around ethical boundaries and addressing regulatory impact for patient advocacy initiatives. The study also contains a chapter with qualitative data from respondents related to the regulatory environment, patient involvement in regulatory issues, and ethical boundaries.

KEY TOPICS

  • Understanding the “advocacy” landscape
  • Strategies to address regulatory impact
  • Clinical trials funding
  • Ethics and patient advocacy relationships

KEY METRICS
  • Do patient advocacy groups that your organizations support/fund clinical trial studies?
  • How much impact do you think initiatives such as the proposed 21st Century Cures Act could have on patient advocacy strategies at your company?
  • What are the ethical boundaries that you adhere to while working with patient advocacy groups?

SAMPLE KEY FINDINGS
  • Evolving regulatory environment is challenging patient advocacy: Changing regulations are also affecting the patient advocacy landscape. Groups are increasingly getting involved with FDA. Patient advocates are influencing the entire drug development lifecycle with the Affordable Care Act and proposed 21st Century Cures Act. In fact, 73% of partners believe the latest changes in regulation will have high to medium impact on patient advocacy strategies. Increasing patient centricity, enabling ease of access, collaborating, and preparing clinical teams will help companies address these regulatory changes.

METHODOLOGY

Best Practices, LLC engaged 74 leaders supporting patient advocacy at 61 biopharmaceutical companies through a benchmarking survey. More than 60% of participants are at the director/ senior director level. Nearly 65% of participants are from the United States.


Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Communications; Medical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Clinical Research; Research; Health Care; Laboratories


Companies Profiled:
AbbVie; Acceleron Pharma; Agendia; Alnylam Pharmaceuticals; Amicus Therapeutics; ApotheCom; Astellas; AveXis; AVROBIO; Baldwin Area Medical Center; Bayer; Biogen; BioMarin; Bionical Emas; Blue Earth Diagnostics; Bluebird Bio; Boehringer Ingelheim; Covance; CRISPR Therapeutics; Daiichi Sankyo; Dermira; Forum Pharmaceuticals; Grifols; GlaxoSmithKline ; Genzyme; Horizon Pharma; Incyte; Ipsen; Janssen; Johnson & Johnson; Lexicon Pharmaceuticals; Lundbeck; Mallinckrodt; Merck; Milestone Pharmaceuticals; MSD; Natera; NexGen Healthcare Communications; Novartis; Novo Nordisk; OTSUKA; Parkway Pantai; Pfizer; Pharmacyclics; Reata Pharmaceuticals; Retrophin; Sage Therapeutics; Sanofi; Servier; Shire; Spark Therapeutics; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; Theravance; Tillotts Pharma; UCB Pharma; Ultragenyx; Wave Life Sciences; Zimmer Biomet; Zogenix; The Mexican Organization for Rare Disorders (OMER)

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.